Oculis will acquire all worldwide development and commercial rights to privosegtor, Accure Therapeutics’ lead candidate for optic neuritis, according to a press release.
August 13, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions.…
ZOC2017217, an eye drop aimed at slowing or reversing the development of cataracts, is undergoing a pilot study ahead of a…
Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to…
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
DENVER — MCO-010, an optogenetic therapy, demonstrated vision improvements for patients with retinitis pigmentosa at 3 years,…
Outlook Therapeutics resubmitted a biologics license application to the FDA for ONS-5010 for the treatment of neovascular…
